A股異動丨藥石科技(300725.SZ)升超7%破頂 獲多家券商唱好
格隆匯1月7日丨藥石科技(300725.SZ)漲幅擴大至7.67%,報155.58元刷新歷史高價,暫成交4.8億元,總市值238.67億元。自去年12月31日,公司發佈向特定對象發行股票上市公吿書。持續受到券商的唱好,光大證券指出,公司定增正式落地,“聚焦+放大”打開成長空間,維持‘“買入’’評級。國海證券表示,定增落地,全球新型分子砌塊龍頭進入發展新時期。國金證券亦維持公司“買入”評級。相信公司相關新藥研發業務的不斷拓展,預計帶來收入的提升和毛利率/淨利率的改善。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.